12th Annual Controversies in Hematologic Malignancies Symposium
Target Audience
Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses and Allied Health Professionals
Learning Objectives
Participants who engage in this educational intervention will be able to:
- Identify current best practice evidence-based guidelines and novel treatment strategies for FLT3 mutant AML.
Describe recommendations designed to improve immunotherapy treatment of multiple myeloma based on current advancements and trial results.
List challenges and treatment options for Non-Hodgkins Lymphoma in non-elderly patients based on updated guidelines.
AGENDA
- Maintenance Strategies after Hematopoietic Cell Transplantation (LISA SAMANAS)
- BMT Survivorship: The Need for Care Continues After Treatment Ends (RACHEL PHELAN)
- Transitioning Inpatient Chemotherapy to the Outpatient Setting (MARY FOURNAGERAKIS)
Name | Company | Role |
---|---|---|
Nirav Shah | Loxo Lilly and Miltenyi Biotech Epizyme Janssen, Kite Pharma, Incyte, Seattle Genetics, Novartis, BMS-Juno, TG Therapeutics, Tundra Therapeutics, Umoja | Consultant Investigator Advisory Board |
Sham Mailankody | PleXus Education, Physician Education Resource, Cancer Network Janssen Oncology, Bristol Myers Squibb and Fate Therapeutics Evicore, Legend Biotech, BioAscend and Optum Oncology | Speaker Investigator Advisory Panel |
Anita D'Souza | Bristol Myers Squibb, Prothena, Janssen Biotech AbbVie, Caelum, Novartis, Regeneron, Sanofi, Takeda, TeneoBio | Consultant Investigator |
John P. Leonard | AbbVie, Astellas, AstraZeneca, Bayer, Beigene, Bristol Myers Squibb, Calithera, Constellation, Caribou Biosciences, Eisai, Lilly, Epizyme, Genmab, Grail, Incyte, Janssen, MEI Pharma, Merck, Mustang Bio, Novartis, Pfizer, Roche, Genentech, Seagen, Second Genome,Sutro | Consultant |
Rachel Phelan | Bluebird Bio Amgen | Advisory Panel Investigator |
Available Credit
- 4.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 4.25 Hours of ParticipationHours of Participation credit.